A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Lung Cancer · Breast Cancer
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2.6
2 insiders sold shares within a month
Since Sep 9, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 416 (planned)
- Started
- Feb 4, 2025
- Main results expected
- Feb 26, 2031
- Fully finished
- Feb 26, 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of participants with adverse events (AEs)
Measured over: Up to 3 years
Number of participants with serious adverse events (SAEs)
Measured over: Up to 3 years
Number of participants with AEs meeting protocol defined dose-limiting toxicity (DLT) critera
Measured over: Up to 3 years
Number of participants with AEs leading to discontinuation
Measured over: Up to 3 years
Number of participants with AEs leading to death
Measured over: Up to 3 years
Number of DLTs that occur during the DLT evaluation period
Measured over: Up to 3 weeks
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06618287 · record last updated 2026-09-23 · checked 2026-11-09 15:47 UTC